Crispr Therapeutics (NASDAQ:CRSP) was downgraded by BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued on Friday, December 13th, BidAskClub reports.

A number of other research firms have also weighed in on CRSP. Goldman Sachs Group raised their price objective on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. ValuEngine upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 1st. Zacks Investment Research lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Chardan Capital reaffirmed a “buy” rating and set a $72.50 price target on shares of Crispr Therapeutics in a report on Monday, November 18th. Finally, William Blair raised shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, November 19th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have issued a buy rating to the stock. Crispr Therapeutics presently has an average rating of “Buy” and an average target price of $71.38.

Shares of NASDAQ:CRSP traded up $0.12 on Friday, hitting $59.44. The company had a trading volume of 1,391,345 shares, compared to its average volume of 941,091. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm’s 50-day simple moving average is $65.98 and its two-hundred day simple moving average is $51.14. Crispr Therapeutics has a 1 year low of $28.95 and a 1 year high of $74.00.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. Equities analysts predict that Crispr Therapeutics will post 0.65 EPS for the current year.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total transaction of $390,000.00. Following the transaction, the director now owns 7,500 shares of the company’s stock, valued at $390,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the sale, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock worth $3,620,760 in the last ninety days. Insiders own 21.40% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Benjamin Edwards Inc. increased its position in Crispr Therapeutics by 96.4% in the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after purchasing an additional 268 shares during the last quarter. NEXT Financial Group Inc increased its position in Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after purchasing an additional 549 shares during the last quarter. US Bancorp DE increased its position in Crispr Therapeutics by 553.7% in the second quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after purchasing an additional 526 shares during the last quarter. Coastal Investment Advisors Inc. bought a new position in Crispr Therapeutics during the third quarter valued at $26,000. Finally, BSW Wealth Partners bought a new position in Crispr Therapeutics during the second quarter valued at $39,000. Hedge funds and other institutional investors own 49.82% of the company’s stock.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Recommended Story: Profit Margin

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link